Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.57 |
| ▸ | PPARA | Q07869 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 3/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 2/20 | 0.42 |
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1503845 | 1.00 | SYK (0.57) | SYKPPARAMAPTCTSKKLK5 | |
| SCHEMBL1504059 | 0.85 | SYK (0.57) | SYKPPARAMAPTCTSKPPARG | |
| SCHEMBL1503940 | 0.84 | SYK (0.49) | SYKPPARAMAPTCTSKKLK5 | |
| SCHEMBL4363469 | 0.81 | SYK (0.57) | SYKPPARAMAPTCTSKKLK5 | |
| SCHEMBL4356869 | 0.81 | SYK (0.57) | SYKPPARAMAPTCTSKKLK5 | |
| SCHEMBL209116 | 0.80 | SYK (0.55) | SYKPPARAMAPTCTSKKLK5 | |
| SCHEMBL207511 | 0.80 | SYK (0.55) | SYKPPARAMAPTCTSKKLK5 | |
| SCHEMBL3911384 | 0.79 | SYK (0.70) | SYKPPARAMAPTCTSKPPARG | |
| SCHEMBL2186497 | 0.79 | SYK (0.57) | SYKPPARAMAPTCTSKKLK5 | |
| SCHEMBL1503843 | 0.79 | SYK (0.57) | SYKPPARAMAPTCTSKKLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2343290-A1 | Diamine derivatives as factor X inhibitors | Daiichi Sankyo Company, Limited (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-20100093785-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093785-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | SYK 1675/4885PPARA 4189/4885MAPT 4343/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | SYK 2089/4885PPARA 4308/4885MAPT 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.